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Abstract
Background: Apolipoprotein E (apoE) is a key component of the lipid metabolism. Polymorphisms at the apoE
gene (APOE) have been associated with cardiovascular disease, lipid levels and lipid-lowering response to statins.
We evaluated the effects on APOE expression of hypercholesterolemia, APOE ε2/ε3/ε4 genotypes and atorvastatin
treatment in Brazilian individuals. The relationship of APOE genotypes and plasma lipids and atorvastatin response
was also tested in this population.
Methods: APOE ε2/ε3/ε4 and plasma lipids were evaluated in 181 normolipidemic (NL) and 181
hypercholesterolemic (HC) subjects. HC individuals with indication for lowering-cholesterol treatment (n = 141)
were treated with atorvastatin (10 mg/day/4-weeks). APOE genotypes and APOE mRNA in peripheral blood
mononuclear cells (PBMC) were analyzed by TaqMan real time PCR.
Results: HC had lower APOE expression than NL group (p < 0.05) and individuals with low APOE expression
showed higher plasma total and LDL cholesterol and apoB, as well as higher apoAI (p < 0.05). Individuals carrying
ε2 allele have reduced risk for hypercholesterolemia (OR: 0.27, 95% I.C.: 0.08-0.85, p < 0.05) and NL ε2 carriers had
lower total and LDL cholesterol and apoB levels, and higher HDL cholesterol than non-carriers (p < 0.05). APOE
genotypes did not affect APOE expression and atorvastatin response. Atorvastatin treatment do not modify APOE
expression, however those individuals without LDL cholesterol goal achievement after atorvastatin treatment
according to the IV Brazilian Guidelines for Dyslipidemia and Atherosclerosis Prevention had lower APOE expression
than patients with desirable response after the treatment (p < 0.05).
Conclusions: APOE expression in PBMC is modulated by hypercholesterolemia and the APOE mRNA level regulates
the plasma lipid profile. Moreover the expression profile is not modulated neither by atorvastatin nor APOE
genotypes. In our population, APOE ε2 allele confers protection against hypercholesterolemia and a less
atherogenic lipid profile. Moreover, low APOE expression after treatment of patients with poor response suggests a
possible role of APOE level in atorvastatin response.
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Background
Dyslipidemia is an important risk factor in the develop-
ment of atherosclerosis and cardiovascular events.
Research on cardiovascular diseases has leaded to a better
knowledge of the molecular basis of atherosclerosis and
the identification of a key role of apolipoprotein (apo) E
in this process [1]. ApoE is a major constituent of trigly-
ceride-rich chylomicrons, very low density lipoprotein
(VLDL) and some subclasses of high density lipoprotein
(HDL) particles, participating in the clearance of these
particles from circulation by serving as a ligand for their
catabolism via low density lipoprotein (LDL) and apoE
receptors [2].
The gene encoding the apoE protein (APOE) is poly-
morphic resulting in three major isoforms (ε2, ε3 and ε4)
caused by two single nucleotide polymorphisms (SNPs)
in the exon 4 of the APOE, resulting in cysteine-arginine
interchanges at residuals 112 and 158 of the protein,
which has been associated with a number of pathophy-
siological conditions, including cardiovascular and neuro-
logical diseases [3].
The inhibitors of the 3-hydroxy-3-methylglutaryl coen-
zyme A reductase (HMGCR), or statins, are among the
most prescribed drugs worldwide and provide extensive
benefits in the prevention of primary and secondary cardi-
ovascular diseases [4]. However, there is considerable
interindividual variation in the lipid-lowering response to
statins, which is attributed to the interaction between mul-
tiple environmental factors and genetic determinants
involved in the pharmacokinetic and pharmacodynamic
pathways of these drugs [5].
The APOE gene is among the most extensively studied
genes involved in the statins pharmacodynamic. The stu-
dies investigating the potential modifying role of APOE
genotypes on lipid response to statin therapy have pro-
duced data frequently contradictory and so far inconclu-
sive [6]. Evidence suggests that allele ε4 carriers appear to
have attenuated lipid-lowering response and ε2 carriers
have enhanced response [5], however differential interpre-
tation of these results among investigators difficult the
consensus [6]. Moreover genome-wide association studies
(GWAS) have also shown an association of the APOE
locus with hypercholesterolemia but they were unsuccess-
ful in establishing its relationship with statin response
when whole-genome platforms were used [7].
The regulation of APOE expression is very complex with
participation of several factors controlling its transcription,
including some factors that also regulate the expression of
other proteins that control the lipid traffic [1]. Neverthe-
less, possible regulation of APOE transcription by poly-
morphisms and statins has been poorly studied.
The purpose of this study is to investigate the effects on
APOE mRNA expression profile of hypercholesterolemia
and APOE genotypes using PBMC from normolipidemics
and hypercholesterolemic individuals. Moreover, we also
analyzed the influence of atorvastatin treatment on
APOE expression in hypercholesterolemic individuals, as
well as the relationship of APOE genotypes with plasma
lipid and atorvastatin response in our population.
Results
Characteristics of study population
Main characteristics of normolipidemic and hypercholes-
terolemic individuals are shown in Table 1. Frequencies of
ethnics, gender, family history of coronary artery disease
(CAD), cigarette smoking and physical activity were simi-
lar between NL and HC groups. However, mean values of
age and body mass index (BMI), as well as frequencies of
menopause, hypertension and obesity were higher in HC
than NL group (p < 0.05). As expected, HC individuals
had a more atherogenic lipid profile showing higher total,
LDL and VLDL cholesterol, triglycerides and ApoB com-
pared with NL subjects (p < 0.05).
Association of hypercholesterolemia and plasma lipids
with APOE gene expression
As represented in the Figure 1A, NL individuals showed
higher levels of APOE mRNA expression in PBMC than
HC individuals at baseline (NL: median 11.7 × 10-5 and
inter-quartile (IQ) range: 7.6 × 10-5 - 20 × 10-5; ATORVA
baseline: median: 8.1 × 10-5 and IQ range: 3.7 × 10-5 -
17 × 10-5; p = 0.004).
Spearman’s correlation test demonstrated that APOE
mRNA expression in PBMC is negatively correlated
with total cholesterol (r = -0.195, p = 0.008) and LDL
cholesterol (r = -0.214, p = 0.004), and positively corre-
lated with apoAI concentration (r = 0.202, p = 0.007)
(data not shown).
Due to the wake lineal correlation and in order to corro-
borate the association of APOE mRNA expression levels
with plasma lipid concentration and hypercholesterolemia,
comparison analyses by grouping patients according to
tercile of APOE mRNA values were performed (first ter-
cile: 2-ΔCt < 7.7x10-5; second tercile: 2-ΔCt: 7.7x10-5 -
17.1x10-5; third tercile: 2-ΔCt > 17.1x10-5). First, second
and third tercile were considered as low, intermediate and
high expression, respectively. As observed in Figure 2,
individuals with low APOE mRNA expression had higher
plasma concentration of total and LDL cholesterol and
apoB and lower levels of apoAI (p < 0.05). Further univari-
ate logistic regression analysis demonstrated that indivi-
duals with mRNA values into the low expression group
had increased risk to hypercholesterolemia than indivi-
duals with higher (intermediate and high expression)
values of APOE expression (OR: 2.06, 95% C.I.: 1.10-3.87,
p = 0.025). Moreover, when compared with the individuals
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with the highest APOE mRNA levels, to belong to the low
expression group represent an increased risk of 2.25 (OR:
2.25, 95% CI:1.08-4.67, p=0.030).
Relationship of APOE genotypes with basal lipids,
atorvastatin response and APOE expression
Genotype and allele frequencies are presented in Table 2.
Frequencies of SNP genotypes were as expected from a
HWE (p > 0.05, data not shown) in both, NL and HC
groups. The genotype distribution was different between
NL and HC groups (p = 0.003) showing higher frequen-
cies of ε2ε3 and ε2ε4 genotypes in NL individuals. ε2
allele was more frequent in NL group (7.7%) than in HC
(1.7%, p < 0.001) and logistic regression analysis showed
that ε2 carriers had decreased risk of hypercholesterole-
mia (OR: 0.27; C.I.: 0.08 - 0.85; p < 0.025), after adjust-
ment for covariates gender, ethnics, history of CAD, age,
hypertension, obesity, cigarette smoking, physical activity
and alcohol consumption.
Individuals carrying the ε2 allele showed lower total
and LDL cholesterol and apoB, as well as higher HDL
cholesterol (p < 0.05) compared with the ε3 and ε4 car-
riers in NL group (Table 3). No differences were
observed on basal plasma lipids in HC group according
to APOE genotypes.
Association between APOE genotypes and basal plasma
lipids in NL and HC individual was further explored in a
multiple linear regression analysis adjusted for covariates
gender, age, ethnics, hypertension, obesity, family history
of CAD, physical activity, cigarette smoking and alcohol
consumption. In women group, menopause status did
not modified APOE genotypes effects, therefore this vari-
able was not included in the regression analysis. In NL
group, the presence of ε2 allele was associated with a sig-
nificant decrease of 11.6, 18.1 and 13.8 mg/dL in values
of total cholesterol, LDL cholesterol and apoB, respec-
tively (Table 4). Moreover, ε2 allele was also associated
with an increment of 9 mg/dL of HDL cholesterol. On
the other hand, presence of ε4 allele was related to an
increment of 6.7, 8.8 and 9.0 of total cholesterol, LDL
cholesterol and apoB, respectively (Table 4). Confirming
the previous results, we did not found any association
between APOE genotypes and basal plasma lipids in HC
individuals in the multiple linear regression model (data
not shown).
No differences were observed on APOE mRNA
expression according to APOE ε2/ε3/ε4 genotypes (p >
0.05, data not shown). Moreover the genotype distribu-
tion among APOE mRNA expression level groups was
similar (c2 = 0.695, 4 df, p = 0.952; data not shown).
Atorvastatin treatment reduced the plasma lipids with
exception of apoAI in ATORVA group (Additional file
1). Results of CK and ALT demonstrated that there
were no muscle or liver adverse reaction cases during
the four-week atorvastin treatment (data not shown).
APOE genotypes did not influence basal and post-
treatment plasma lipids in individuals treated with ator-
vastatin (Table 5). Further multiple linear regression
Table 1 Demographic and laboratory characteristics of study groups
Parameter Hypercholesterolemic
(n = 181)
Normolipidemic
(n = 181)
p-value
Age, years 56.1 ± 10.8 46.9 ± 6.8 < 0.001
Ethnics [European/African], % 62/38 65/35 0.581
Gender, % of women 67 73 0.205
Menopause, % 52 19 < 0.001
Family history of CAD, % 55 45 0.062
Hypertension, % 57 36 < 0.001
Obesity, % 29 15 0.002
Cigarette smoking, % 16 18 0.673
Physical activity, % 49 45 0.553
BMI, kg/m2 27.8 ± 4.1 26.2 ± 4.2 < 0.001
Total cholesterol, mg/dL 270 ± 41 173 ± 18 < 0.001
LDL cholesterol, mg/dL 183 ± 36 98 ± 18 < 0.001
HDL cholesterol, mg/dL 57 ± 14 58 ± 12 0.386
Triglycerides, mg/dL 150 ± 65 82 ± 28 < 0.001
VLDL cholesterol, mg/dL 30 ± 13 16 ± 6 < 0.001
ApoAI, mg/dL 136 ± 26 141 ± 26 0.101
ApoB, mg/dL 143 ± 27 85 ± 23 < 0.001
Non-continuous variables are compared by chi-square test. Continuous variables are presented as media ± SD and compared by t test. CAD, coronary artery
disease; LDL, low density lipoprotein; HDL, high density lipoprotein; VLDL, very low density lipoprotein; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B.
Conversion factors to convert to Systeme Internacional (SI) units are 0.02586 for cholesterol (mmol/l), 0.01129 for triglycerides (mmol/l) and 0.01 for
apolipoproteins (g/l).
Cerda et al. Lipids in Health and Disease 2011, 10:206
http://www.lipidworld.com/content/10/1/206
Page 3 of 11
Figure 1 PBMC APOE mRNA expression in normolipidemic (NL) and hipercolesterolemic individuals before (HC - BASAL) and after
treatment with 10 mg/day of atorvastatin (HC- ATORVA) [A] and according to LDL cholesterol goal achievement in response to
atorvastatin [B]. Values are presented as dispersion graph with bars indicating median and interquartile range and compared by Mann-Whitney
U test or Wilcoxon signed test.
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analysis confirmed these results (data not shown). More-
over, 10 mg/day atorvastatin treatment did not modify
the APOE mRNA expression (p > 0.05; Figure 1A).
Despite the absence of atorvastatin effects on APOE
mRNA expression, those individuals without LDL
cholesterol goal achievement according to the IV Brazi-
lian Guidelines for Dyslipidemia and Atherosclerosis
Prevention [8] had lower expression (p = 0.009; Figure
1B) than patients with desirable response after the
treatment.
Figure 2 Plasma lipid profile according to APOE mRNA expression levels. Patients were grouped in levels of APOE mRNA expression
according to tercile values (first tercile [low]: 2-ΔCt < 7.7x10-5; second tercile [intermediate]: 2-ΔCt: 7.7 x10-5 - 17.1 x10-5; third tercile [high]: 2-ΔCt >
17.1 x10-5) and plasma lipids were compared among the groups by one way ANOVA and Tukey test. TC, total cholesterol; LDL-c, low density
lipoprotein cholesterol; HDL-c, high density lipoprotein cholesterol; TG, triglycerides; apoAI, apolipoprotein AI; apoB, apolipoprotein B; (*), p <
0.05. Conversion factors to convert to Systeme Internacional (SI) units are 0.02586 for cholesterol (mmol/l), 0.01129 for triglycerides (mmol/l) and
0.01 for apolipoproteins (g/l).
Table 2 Genotype and allele frequencies of APOE polymorphisms in hypercholesterolemic and normolipidemic
individuals
Genotypes ε2ε2 ε2ε3 ε2ε4 ε3ε3 ε3ε4 ε4ε4
HC (n = 181) 0.0% (0) 2.8% (5) 0.6% (1) 66.3% (120) 26.5%(48) 3.8% (7)
NL (n = 181) 0.6% (1) 9.4% (17) 5.0% (9) 61.3% (111) 22.7%(41) 1.1% (2)
c2 = 17.624; 5 df; p = 0.003
Alleles ε2 ε3 ε4
HC 1.7% 80.9% 17.3%
NL 7.7% 77.4% 14.9%
c2 = 15.223; 2 df; p < 0.001
Allele O.R. 95%C.I. p-value
ε3 1.00 – –
ε2 0.27 0.08-0.85 0.025
ε4 1.31 0.76-2.26 0.331
Number of individuals is in parenthesis. HC, hypercholesterolemic; NL, normolipidemic; df, degrees of freedom; O.R., odds ratio; C.I. confidence interval. O.R.
values and 95% C.I. were obtained from logistic regression analysis using hypercholesterolemia as dependent variable with gender, ethnics, history of coronary
artery disease, age, hypertension, obesity, cigarette smoking, physical activity and alcohol consumption as covariates for the model. Influence of ε2 and ε4 alleles
on risk for hypercholesterolemia was accessed comparing with the reference allele ε3.
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Discussion
Diverse studies have proposed an important role of the
APOE in hypercholesterolemia and statin response
based in this association with APOE ε2/ε3/ε4 genotypes,
but little information is known about the relationship of
these variables with the expression status of APOE.
Here, we describe the mRNA expression profile in
PBMC from NL individuals and HC patients treated
with atorvastatin.
Absence or structural mutations of APOE cause signifi-
cant disorders in lipid metabolism and cardiovascular
diseases. Deficiency of apoE results in massive accumula-
tion of remnant lipoproteins, leading to severe hypercho-
lesterolemia and atherosclerosis in human and apoE
knockout mice [1]. Here, we reported that HC individuals
have lower APOE mRNA expression than NL individuals,
which is concordant with the previous information
related to apoE deficiency.
The APOE mRNA expression is extremely complex
with regulation in a tissue-specific manner and in
response to cellular changes and extra and intra-cellular
factors [1]. The expression of cholesterol acceptors in the
efflux process such as apoAI, as well as transporter pro-
teins involved in this process have been described to acti-
vate APOE transcription in human adipocytes and
macrophages [9,10]. Accordingly, we observed that indi-
viduals with low expression of APOE present a decreased
apoAI plasma concentration. Moreover, we also reported
Table 3 Influence of APOE polymorphisms on basal serum lipids in normolipidemic and hipercholesterolemic
individuals
Parameter ε2 ε3 ε4 p-value
Normolipidemics (18) (111) (43) –
Total cholesterol, mg/dL 160 ± 23a 173 ± 18b 177 ± 15b 0.003
LDL cholesterol, mg/dL 81 ± 18a 99 ± 18b 105 ± 16b < 0.001
HDL cholesterol, mg/dL 65 ± 11a 57 ± 12b 56 ± 12b 0.023
VLDL cholesterol, mg/dL 14 ± 5 17 ± 6 16 ± 5 0.179
Triglycerides, mg/dL 72 ± 25 84 ± 28 80 ± 26 0.179
ApoAI, mg/dL 150 ± 20 140 ± 25 137 ± 31 0.205
ApoB, mg/dL 71 ± 19a 86 ± 23b 90 ± 22b 0.011
Hypercholesterolemics (5) (120) (55) –
Total cholesterol, mg/dL 253 ± 25 271 ± 43 267 ± 31 0.668
LDL cholesterol, mg/dL 166 ± 22 183 ± 39 181 ± 25 0.622
HDL cholesterol, mg/dL 62 ± 18 57 ± 14 56 ± 13 0.679
Triglycerides, mg/dL 133 ± 42 151 ± 71 148 ± 52 0.713
VLDL cholesterol, mg/dL 27 ± 8 30 ± 14 30 ± 10 0.713
ApoAI, mg/dL 140 ± 34 138 ± 29 132 ± 19 0.418
ApoB, mg/dL 128 ± 29 143 ± 28 143 ± 25 0.450
Number of individuals is in parenthesis. Values are expressed as media ± SD and compared by one way ANOVA. HC, hypercholesterolemic; NL, normolipidemic;
LDL, low density lipoprotein; HDL, high density lipoprotein; VLDL, very low density lipoprotein; ApoAI, apolipoprotein AI; ApoB, apolipoprotein B. ε2 represent
ε2ε2 and ε2ε3 carriers; ε3 symbolize ε3ε3 genotype and ε4 represent ε3ε4 and ε4ε4 individuals. a, b, different letters at the same line represent statistical
significance. Conversion factors to convert to Systeme Internacional (SI) units are 0.02586 for cholesterol (mmol/l), 0.01129 for triglycerides (mmol/l) and 0.01 for
apolipoproteins (g/l).
Table 4 Influence of APOE genotypes on basal serum lipids in normolipidemic individuals by multiple linear
regression analysis
Variable ε2 p-value ε3 p-value ε4 p-value
B (SE) B (SE) B (SE)
Total cholesterol -11.6 (5.3) 0.030 -1.0 (3.3) 0.753 6.7 (3.3) 0.047
LDL cholesterol -18.1 (5.2) 0.001 -0.7 (3.4) 0.847 8.8 (3.4) 0.010
HDL cholesterol 9.0 (3.4) 0.009 -1.2 (2.2) 0.568 -1.8 (2.2) 0.399
VLDL cholestrol -1.8 (1.5) 0.236 0.8 (0.9) 0.352 -0.3 (0.9) 0.799
ApoB -13.8 (6.9) 0.046 -2.6 (4.2) 0.534 9.0 (4.5) 0.047
ApoAI 11.3 (7.6) 0.138 0.7 (4.5) 0.879 -5.4 (4.9) 0.269
B and (SE) represent regression coefficient and standard error and are expressed in mg/dL. B values were obtained from multiple linear regression analysis
introducing gender, ethnics, family history of coronary artery disease, age, hypertension, obesity, cigarette smoking, physical activity and alcohol consumption as
covariates. HDL, high density lipoprotein; LDL, low density lipoprotein; VLDL, very low density lipoprotein; apoB, apolipoprotein B; apoAI, apolipotrotein AI.
Conversion factors to convert to Systeme Internacional (SI) units are 0.02586 for cholesterol (mmol/l), 0.01129 for triglycerides (mmol/l) and 0.01 for
apolipoproteins (g/l).
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that these individuals have increased concentrations of
total and LDL cholesterol and apoB. The relation of
plasma levels of LDL cholesterol with APOE expression
in PBMC was previously reported in children with obe-
sity [11]. The increased concentrations of particles which
depend on the LDL receptor (LDLR) for their clearance
from plasma is consistent with the key role of apoE as a
high affinity ligand for the LDLR in the cholesterol
homeostasis [12].
APOE allele frequencies have demonstrated to be het-
erogeneous among different populations, but the ε3 allele
is almost invariably the most common and ε2 the rarest
allele [13]. In this study, the frequencies of APOE alleles
observed in the overall population (ε2: 5%, ε3: 79% and
ε4:16%) were similar to earlier studies in European des-
cendant population [13,14], African American [15] and
Brazilian populations [16].
Several genetic factors have been related to hypercholes-
terolemia, however in most of the cases the contribution
of these genetic factors to the risk for hypercholesterole-
mia depends on environmental factors. Our results
showed differences in genotype and allele frequencies
between normolipidemic and hypercholesterolemic
groups, suggesting that APOE ε2 allele confers protection
against hypercholesterolemia. This characteristic persists
even after adjustment for covariates that have been largely
associated with hypercholestolemia, such as gender, eth-
nics, history of CAD, age, hypertension, obesity, cigarette
smoking and physical activity, suggesting that APOE ε2
could be considered an independent factor that protect
against hypercholesterolemia in our sample population.
Ferreira and co-workers [16] did not found differences
in APOE ε2/ε3/ε4 genotypes between normolipidemic
and dyslipidemic Brazilian individuals. On the other
hand, and in line with our results, it has been reported
higher frequency of ε2 allele in normolipidemic than
hypercholesterolemic individuals from South America
[17]. Moreover, a previous study in the Brazilian popula-
tion reported that, compared with the ε2 allele, the pre-
sence of ε3 allele increases more than two times the risk
for dyslipidemia (OR: 2.31, CI:1.06-5.06) [18], which is in
agreement with our results.
The effects of APOE polymorphisms on plasma lipids
have been described by several studies and the evidence
suggests that APOE ε2 is associated with lower, whereas ε4
with higher, concentrations of plasma total cholesterol,
LDL cholesterol and apoB in comparison with the ε3 allele
[19]. We reported a less atherogenic lipid profile of ε2
allele, as well as a contribution of ε4 allele for higher total
and LDL cholesterol and apoB in normolipidemic
Table 5 Influence of APOE genotypes on serum lipids in hypercholesterolemic individuals treated with atorvastatin (10
mg/day/4-weeks)
Parameter ε2 (5) ε3 (92) ε4 (44) p-value
Total cholesterol, Basal 253 ± 25 284 ± 39 275 ± 27 0.100
mg/dL Treatment 174 ± 28 198 ± 31 198 ± 27 0.285
Change, % -32 ± 6 -30 ± 10 -28 ± 8 0.332
LDL cholesterol, Basal 166 ± 22 194 ± 37 188 ± 21 0.166
mg/dL Treatment 96 ± 20 116 ± 28 119 ± 22 0.262
Change, % -42 ± 9 -40 ± 13 -37 ± 10 0.408
HDL cholesterol, Basal 62 ± 18 57 ± 15 55 ± 11 0.534
mg/dL Treatment 55 ± 14 55 ± 14 53 ± 10 0.745
Change, % -11 ± 11 -3 ± 11 -3 ± 9 0.270
VLDL cholesterol, Basal 27 ± 8 32 ± 14 31 ± 11 0.672
mg/dL Treatment 24 ± 12 26 ± 12 26 ± 9 0.880
Change, % -10 ± 38 -14 ± 30 -12 ± 25 0.902
Triglycerides, Basal 133 ± 42 159 ± 72 155 ± 53 0.672
mg/dL Treatment 118 ± 58 130 ± 58 131 ± 43 0.880
Change, % -10 ± 38 -14 ± 30 -12 ± 25 0.902
ApoAI, Basal 140 ± 34 138 ± 29 132 ± 19 0.418
mg/dL Treatment 151 ± 54 140 ± 28 133 ± 24 0.259
Change, % +6 ± 16 +2 ± 11 +1 ± 13 0.650
ApoB, Basal 128 ± 29 143 ± 28 143 ± 25 0.532
mg/dL Treatment 97 ± 23 99 ± 21 97 ± 19 0.984
Change, % -24 ± 7 -30 ± 13 -31 ± 11 0.494
Number of individuals is in parenthesis. -/+ symbols in change indicate reduction or increment of each parameter. Values are presented as media ± SD and
compared by one way ANOVA. LDL, low density lipoprotein; HDL, high density lipoprotein; VLDL, very low density lipoprotein. ε2 : ε2ε2 and ε2ε3 genotypes; ε3:
ε3ε3 genotype; ε4: ε3ε4 and ε4ε4 genotypes. Conversion factors to convert to Systeme Internacional (SI) units are 0.02586 for cholesterol (mmol/l), 0.01129 for
triglycerides (mmol/l) and 0.01 for apolipoproteins (g/l).
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individuals. However, the association between APOE poly-
morphisms and plasma lipids were detected exclusively in
the normolipidemic group. In agreement with this charac-
teristic, an association of APOE genotypes with basal
plasma lipids in normolipidemic individuals, but not in
dyslipidemic patients, was previously reported in our popu-
lation [16]. The authors described that ε2 allele carriers had
significantly lower total, LDL and non-HDL cholesterol
compared to ε3 and ε4 allele carriers only in normolipi-
demic individuals. Moreover, other studies were not able
to demonstrate any association between APOE ε2/ε3/ε4
genotypes and total and LDL cholesterol in patients with
familial hypercholestolemia [20] and polygenic dyslipide-
mia [21,22]. Nerveless, the lack of association of APOE
polymorphisms with plasma lipids in hypercholesterolemic
patients in our sample seems to be attributable to the small
number of individuals carrying the ε2 allele that could be
considered an important limitation of our study.
The variation on plasma lipids according to APOE ε2/
ε3/ε4 genotypes are believed to stem mainly from struc-
tural and biophysical properties of apoE isoforms [3].
ApoE4-containing lipoproteins exhibit a high binding abil-
ity to their receptors that cause a more efficient catabolism
and an accelerated clearance of chylomicrons and VLDL-
remnants, leading to down regulation of LDLR and
HMGCR and to increased LDL cholesterol levels in
plasma. On the contrary, lipoproteins containing the
apoE2 isoform present lower affinity compared to apoE4
and apoE3 isoforms that result in decreased cholesterol
levels.
In the present study, no differences were observed in the
change of lipid levels in response to atorvastatin treatment
according to APOE genotypes. Although many studies
have evaluated the influence of APOE polymorphism on
statin response, some of these studies had controversial
results. Whereas there is a strong line of evidence linking
APOE ε2/ε3/ε4 genotypes with the efficacy of statin treat-
ment [23-26], other studies did not reveal any association
between APOE genotypes and response to treatments with
various statins [27-29]. Commonly, evidence supports that
APOE ε3 allele is associated with better response than ε4
allele in term of LDL cholesterol decrease and, in addition,
individuals carrying the ε2 allele have greater reduction of
LDL cholesterol than ε3 homozygotes [30]. These differ-
ences result from the improved activity of HMGCR in ε2
compared to ε3 allele carriers due to the modulation of
intracellular cholesterol by the upregulation of hepatic
LDLR, which has lower affinity for the apoE2 isoform that
results in an improved response of ε2 allele carriers to the
inhibition of HMGCR by statins. On the other hand, the
LDLR presents higher affinity for apoE4 isoform and the
effect of statin therapy is diminished in ε4 allele carriers
when compared to ε2 or ε3 [3].
In the last years, GWAS have provided new perspectives
and a more comprehensive approach for identifying
genetic loci associated to statin response. Thompson et al.
(2009), using a platform of 291, 988 SNPs did not observe
any association between genotypes and atorvastatin
response at beginning, when 1, 984 individuals were ana-
lyzed, however further analysis in 5745 individuals from
the Treating to New Target (TNT) trial using a candidate
gene approach reported a strong association between
APOE ε2/ε3/ε4 genotypes and LDL cholesterol statin
response [31]. Furthermore, a recent study has evaluated
the response to diverse statins using a GWAS approach
involving nearly 4, 000 individuals from three different
trials of statin efficacy [Cholesterol and Pharmacogenetics
(simvastatin), Pravastatin/Inflammation CRP evaluation
(pravastatin) and TNT (atorvastatin)] [32]. The authors
did not found any association between APOE SNPs and
statin response, however the SNP rs4429638, located in
the APOC1 gene and near APOE, was associated with
change LDL cholesterol suggesting a possible involvement
of APOE locus in statin efficacy.
Despite the number of studies investigating the response
to statins according to APOE genotypes, the effect of
HMGCR inhibitors on apoE protein and mRNA expres-
sion has been poorly studied, particularly using in vivo
models. Atorvastatin and cerivastatin demonstrated to
reduce apoE protein secretion and APOE mRNA expres-
sion in THP-1 derived macrophages after 24h of treatment
in a dose dependent manner [33]. Conversely, in cultured
human monocyte-derived macrophages, lovastatin
increased APOE mRNA levels but decreased apoE secre-
tion [34], phenomena that the authors attributed to the
increase of apoE not destined for secretion. On the other
hand, regarding in vivo studies, Guan et al. reported that
APOE mRNA levels in mononuclear cells of hyperlipi-
demic diabetic patients taking simvastatin (5-10 mg/day)
did not differ from those without statin treatment [35].
These contradictory results from in vitro experiments and
the data reported for Guan and co-workers and our obser-
vations in PBMC from hypercholesterolemic individuals
(not change after 10 mg/day atorvastatin treatment) could
be explained by the differences in the cellular models used
by the authors. Moreover, we observed that patients with-
out LDL cholesterol goal achievement had lower APOE
mRNA expression that could suggest a possible involve-
ment of the modulation of this gene in the statin response.
Conclusions
Hypercholesterolemic patients had lower APOE mRNA
levels than normolipidemic individuals and the APOE
expression levels were associated with differences in the
plasma lipid profile, corroborating the key role of the
APOE in the cholesterol metabolism and suggesting that
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APOE mRNA expression may be a good marker for
hypercholesterolemia in our sample population. More-
over, although there was no effect of ε2/ε3/ε4 poly-
morphisms on APOE gene expression, the presence of
ε2 allele confers protection against hypercholesterolemia
in Brazilian subjects. Moreover, there was no evidence
of an involvement of APOE genotypes with atorvastatin
lipid-lowering response and the atorvastatin treatment
does not modify the mRNA expression in hypercholes-
terolemic subjects, however the low APOE mRNA
expression after treatment showed by individuals with
poor cholesterol lowering-response suggests a possible
involvement of APOE level in atorvastatin response.
Methods
Study population and therapeutic protocol
Characteristic of study population and therapeutic proto-
col were previously described [36]. Three-hundred-sixty-
two (255 women and 107 men, aged 29 to 81 y) indivi-
duals were randomly selected at the University Hospital
of University of Sao Paulo and the Institute Dante Pazza-
nese of Cardiology, Sao Paulo city, Brazil. One-hundred-
eighty-one subjects were classified as hypercholesterole-
mic (HC) according to the IV Brazilian Guidelines for
Dyslipidemia and Atherosclerosis Prevention [8] and 181
were considered normolipidemics (NL) LDL cholesterol
< 3.36 mmol/L (130 mg/dL)]. Individuals with diabetes
mellitus; hypertriglyceridemia [triglycerides > 4.42 mmol/
L (350 mg/dL)]; liver, renal or thyroid disease; pregnant
women or under treatment of oral contraceptives; and
other causes of secondary dyslipidemia were not included
in the study.
HC individuals went through a four-week washout hav-
ing a low fat diet according to the American Heart Asso-
ciation recommendation [37]. One-hundred-forty-one
individuals from HC group had indication of lowering-
cholesterol drug therapy in order to reach the LDL choles-
terol goal according to the IV Brazilian Guidelines for
Dyslipidemia and Atherosclerosis Prevention [8]. After-
wards, these individuals were treated with 10 mg/day of
atorvastatin during 4 weeks (ATORVA group). Serum
lipids were measured to evaluate atorvastatin cholesterol-
lowering response. The study protocol was approved by
the ethics committees of the Institute Dante Pazzanese of
Cardiology, University Hospital and the School of Pharma-
ceutical Sciences of the University of the Sao Paulo. Each
individual agreed to participate in the study by signing an
informed consent.
Biochemical measurements
Blood samples were collected after an overnight (12 h)
fast. ATORVA patients had blood drown previous and
after the 4-week atorvastatin treatment. Plasma total
cholesterol, HDL cholesterol and triglycerides were mea-
sured by routine enzymatic colorimetric methods. Plasma
apo AI and apo B were measured by nephelometry. LDL
and VLDL cholesterol were estimated by Friedewald for-
mula [38]. Serum ALT and CK concentrations were deter-
mined by kinetic methods to evaluate atorvastatin effects
on liver and muscle tissues.
APOE genotyping
Genomic DNA was extracted from EDTA-treated blood
samples using salting out procedure [39]. SNPs rs7412
and rs429358, that determinate the APOE ε2, ε3 and ε4
alleles were analyzed by allelic discrimination using Taq-
Man real time PCR system. Validated SNP genotyping
assays (ID number C_904973_1 for rs429358 and
C_904973_1 for rs7412) were purchased from Applied
Biosystems (Applied Biosystems, CA, USA). Both SNP
genotyping reactions were optimized in a total volume of
8 μl using 20 ng of DNA and fluorescence was detected
in a 7500 Fast Real-Time PCR system (Applied Biosys-
tems, CA, USA). Control samples with known APOE
genotypes were included in each PCR run, which were
analyzed by the alternative PCR-RFLP method [40].
APOE mRNA quantification in PBMC
APOE mRNA expression was measured in individuals
from NL (n = 88) and ATORVA (n = 94) groups. EDTA-
anticoagulated blood samples were used to obtain per-
ipheral blood mononuclear cells (PBMC) as previously
described [41] and immediately used for RNA extraction.
Total RNA was extracted from PMBC using TRIzol®
Reagent (Invitrogen-Life Technologies, CA, USA) follow-
ing the manufacturer’s suggested protocol. RNA was dis-
solved in DEPC-treated water and the concentration was
measured by spectrophotometry using the NanoDrop®
(NanoDrop Technologies INC., DE, USA). RNA integrity
was evaluated using the bioanalyzer®2100 (Agilent tech-
nologies, CA, USA). Samples with RNA integrity number
(RIN) lower than 5 were not used for mRNA experi-
ments. cDNA was produced from 1 μg of total RNA by
Superscript™ II Reverse Transcriptase (Invitrogen-Life
Technologies, CA, USA).
APOE mRNA expression was measured by quantita-
tive TaqMan real-time PCR (qPCR). The assay ID
Hs00171168_m1 was used to access the APOE mRNA
detection. Genorm software http://medgen.ugent.be/
genorm was used to select the most stable among
six endogenous reference genes [ubiquitin C (UBC),
glyceraldehyde-3-phosphate dehydrogenase (GAPD),
beta-2-microglobulin (B2M), Hypoxanthine phosphori-
bosyl-transferase I (HPRTI), succinate dehydrogenase
complex, subunit A (SDHA) and hydroxymethyl-bilane
synthase (HMBS)], and the most stable in the
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experimental conditions was UBC. The sequence of pri-
mers and probes used for UBC are described allows:
Forward, 5’-ATTTGGGTCGCGGTTCTTG-3’; reverse,
5’-TGCCTTGACATTCTCGAT GGT-3’; and probe,
VIC -TCGTCACTTGACAATGC- MGB/NFQ. The
qPCR assays were carried out in 96 well plates using a
7500 Fast Real-Time PCR system (Applied Biosystems,
CA, USA). The relative quantification of APOE mRNA
was calculated by the comparative Ct method using the
formula 2-ΔCt [42].
Statistical Analysis
Statistical analyses were performed using SPSS v.15 for
windows (SPSS Inc., Madrid, Spain) and Minitab v.15 sta-
tistical software (Minitab Inc. State College, PA). The
allele frequencies and genotype distribution were esti-
mated by gene counting. SNPanalyzer software v. 1.0 [43]
was used to verify whether the genotypes distribution
were in Hardy-Weinberg equilibrium (HWE) using the
expectation-maximization algorithm. Differences in non-
continuous variables, genotype and allelic distributions
were compared by chi-square test. Normality distribution
for all continuous variables was tested by Kolmogorov-
Smirnov test and skewed variables were log transformed
to improve normality for statistical analysis. Differences
in mean values were evaluated by t-test or one-way
ANOVA using Tukey post-hoc test. Paired t-test was
used to analyze the effects of treatment in ATORVA
group. In order to evaluate effects of APOE genotypes on
the different variables, individuals were classified into
three phenotypes: 1) E2 group, carrying the ε2ε2 and
ε2ε3 genotypes; 2) E3 group, carrying the ε3ε3 genotypes;
and 3) E4 group carrying either ε3ε4 or ε4ε4 genotypes.
Individuals with the ε2ε4 were not assigned to any group
and they were therefore excluded for the analysis. Mann
Whitney U test or Kruskal-Wallis (two or three indepen-
dent samples) or Wilcoxon signed rank test (pared sam-
ples) were used to evaluate differences in APOE mRNA
gene expression. Correlations of APOE expression with
other continuous variables were accessed by Spearman
correlation test. Individuals were grouped in three groups
(terciles) according to APOE expression values and
plasma lipid concentrations were then compared among
the groups using one-way ANOVA and Tukey post-hoc
test. Multiple logistic regression analysis was used to
examine the association of APOE genotypes with
hypercholesterolemia including adjustment for relevant
covariates. Multiple linear regression analysis was per-
formed introducing variables of interest as dependent
variables and APOE genotypes together to relevant cov-
ariates as independent variables, which regression coeffi-
cient were obtained for each independent variable.
Statistical significance was set for p < 0.05.
Additional material
Additional file 1: Supplementary table. Influence of 10 mg/day/4-
weeks atorvastatin treatment on plasma lipids in ATORVA group (n =
141). Lipid plasma concentrations in individuals of the ATORVA group at
baseline and after 10 mg/day/4-weeks atorvastatin treatment.
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